Product Description
recombinant human GDF-5 coated onto beta-tricalcium phosphate
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Scil Technology
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Other|Alveolar Bone Loss
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00519155 |
Scil-MD05-C02 | P2 |
Unknown status |
Alveolar Bone Loss |
2008-10-01 |
2019-03-21 |
Treatments |
|
2006-005883-25 |
Scil-MD05-C02 | P2 |
Completed |
Unknown |
2008-08-26 |
2022-03-12 |
Treatments |
|
2005-003391-37 |
Sinus Lift Study | P2 |
Completed |
Unknown |
2008-03-04 |
2022-03-12 |
Treatments |
|
NCT00520377 |
Scil-MD05-C01 | P2 |
Unknown status |
Other |
2007-12-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/24/2024 |
News Article |
Belltopper Mineralisation Modelling Defines Prospectivity |
|
08/22/2024 |
News Article |
Significant Results From Historical Drill Hole Infill Assay Program at Belltopper |
|
08/29/2023 |
News Article |
Booz Allen Opens New Pax River Mission Systems Integration Facility in California, Maryland |
|
11/01/2021 |
PubMed |
Generation and Role of Calpain-Cleaved 17-kDa Tau Fragment in Acute Ischemic Stroke. |
|
08/12/2021 |
PubMed |
A dataset of the mid-brunhes period at site MD05-2925, Solomon Sea: Surface-subsurface planktonic foraminifera stable C-O isotope and Mg/Ca ratios. |